Seena Patel, DMD
Orofacial Pain · Phoenix, AZNPI 1790040749
Payments from drug & device makers
What this record shows
6 manufacturers reported payments, led by Henry Schein, Inc. at 46.3% of the total. Reporting peaked in 2022 at $1,736 and has fallen 92.0% since, to $138 in 2025.
Across 30 payments — averaging $107.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Henry Schein, Inc.$2K
- AbbVie$1K
- Impel Pharmaceuticals Inc.$136
- Promius Pharma LLC$128
- Lundbeck LLC$114
- Teva Pharmaceuticals USA, Inc.$64
What the payments were for
- Speaking & faculty fees$1,50046%
- Food & beverage$1,73854%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Henry Schein, Inc. | 1 | $1,500 |
| AbbVie(2 entities) | 25 | $1,296 |
| Impel Pharmaceuticals Inc. | 1 | $136 |
| Promius Pharma LLC | 1 | $128 |
| Lundbeck LLC | 1 | $114 |
| Teva Pharmaceuticals USA, Inc. | 1 | $64 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few orofacial pain providers in Arizonato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dexamethasone | 68 | $11,929 |
| Betamethasone Diprop AugmentedBetamethasone Dipropionate | 30 | $2,939 |
| Oxcarbazepine | 11 | $1,563 |
| Gabapentin | 35 | $931 |
| Fluocinonide | 14 | $822 |
| Duloxetine Hcl | 21 | $516 |
| Clonazepam | 37 | $383 |
| Clotrimazole | 17 | $272 |
| Nystatin | 14 | $239 |
| Sumatriptan Succinate | 15 | $135 |
| Methylprednisolone | 15 | $83 |
Paid to pharmacies, not to this prescriber.
Other orofacial pain in Phoenix
- Dharti PatelPhoenix$1K
- Rebecca SchafferPhoenix$1K
- Antonia Teruel CastellonScottsdale$5K
- Jeffrey WightMesa$563
- Mandeep VermaniMesa$174
- Georgia Peterson-HoulePeoria$19
- Imran PatelTucson$17
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.